Our study reveals that the levels of sPD-L1 or IL-10 in the serum or PD-1+ Bregs in the PBMCs of breast cancer patients might be predictors for immunotherapy, and combination PD-L1 antagonist and CD40 agonist Abs might be a more efficient immunotherapy for TNBC. Here, IL10 is linked to breast carcinoma.